TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.27 USD
+0.09 (1.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.13 -0.14 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
TScan Therapeutics, Inc. [TCRX]
Reports for Purchase
Showing records 21 - 40 ( 41 total )
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/101 Data at ASH?23 in Heme Malignancies Remains Key Catalyst; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UntitledTCR-T?s Continue Assault on Heme/Solid Tumors; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at OUTPERFORM; Look No Further, TCRX Found Your Target
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 Data of TSC-100 and TSC-101 Points Towards Future Positive Narrative
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TScan''s Pipeline Reports Progress On All Fronts (Liquid Solid Tumors); Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Newly Announced Amgen Partnership Highlights The Power of TargetScan
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Formidable TCR Platform Positioned for Future Growth; Reit. Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TScan Maps Out Solid Tumor Strategy at Investor Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Tumor INDs on Horizon in 4Q22; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expanding TCR-T Programs On Track with Phase 1 Umbrella Data set for YE22; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-200 Series Featured at KOL Event Underscore Tools to Unlock True Solid Tumor Prize
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data-Rich Year Ahead for TScan; Reit. Buy and Lowering Our PT to $15 From $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Growth Seen Across Pipeline; Reit. Buy and $21 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As CAR-T Programs Scream "Look at Me" During ASH, We Look to the Future Impact of TCR-Ts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A